DNAnexus Recognized by Frost & Sullivan for Ability to Integrate and Synchronize Diverse Clinical and Multi-omics Data
Leading cloud-based enterprise platform for precision health data empowers biopharma companies with actionable…
DNAnexus Recognized by Frost & Sullivan for Ability to Integrate and Synchronize Diverse Clinical and Multi-omics Data
Leading cloud-based enterprise platform for precision health data empowers biopharma companies with actionable…
DNAnexus Recognized by Frost & Sullivan for Ability to Integrate and Synchronize Diverse Clinical and Multi-omics Data
Leading cloud-based enterprise platform for precision health data empowers biopharma companies with actionable…
DNAnexus Recognized by Frost & Sullivan for Ability to Integrate and Synchronize Diverse Clinical and Multi-omics Data
Leading cloud-based enterprise platform for precision health data empowers biopharma companies with actionable…
DNAnexus Recognized by Frost & Sullivan for Ability to Integrate and Synchronize Diverse Clinical and Multi-omics Data
Leading cloud-based enterprise platform for precision health data empowers biopharma companies with actionable…
Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg
– Both pivotal studies achieved primary endpoints of LS mean reduction in LDL-C…
Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg
– Both pivotal studies achieved primary endpoints of LS mean reduction in LDL-C…
Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg
– Both pivotal studies achieved primary endpoints of LS mean reduction in LDL-C…
Blue Lake Biotechnology Reports Additional Promising Clinical Data from Ongoing Pediatric Clinical Study of Intranasal RSV Vaccine BLB201
Company leaders to speak today during the open public hearing session of…
Investigational Epcoritamab (DuoBody CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis
Media ReleaseCOPENHAGEN, Denmark; December 8, 2024 Preliminary analyses from the EPCORE® CLL-1…
